Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
10 hedge funds and large institutions have $2.33M invested in Intellipharmaceuticals International Inc. in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 14 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
42% less capital invested
Capital invested by funds: $3.99M → $2.33M (-$1.66M)
58% less funds holding
Funds holding: 24 → 10 (-14)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$5.33K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.23K |
| 3 |
Morgan Stanley
New York
|
+$501 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$301 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ATC
Argent Trust Co
Nashville,
Tennessee
|
-$26K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$17K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$13K |
| 4 |
VAM
Verity Asset Management
Durham,
North Carolina
|
-$13K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12K |
IPCI Hedge Fund Activity: Q3 2018 in Review
10 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q3 2018, worth a combined $2.33M — down 42% from $3.99M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IPCI and 0 opened new positions — a net loss of 14 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Toronto Dominion Bank, adding an estimated $5.33K. The largest seller was Argent Trust Co, exiting entirely with an estimated $26K sold.
- 10 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q3 2018, down from 24 in Q2 2018.
- Funds reported $2.33M of Intellipharmaceuticals International Inc. stock for Q3 2018, down 42% quarter-over-quarter.
- 0 funds opened new Intellipharmaceuticals International Inc. positions in Q3 2018 and 14 closed out, a net change of -14 holders.
- The largest Intellipharmaceuticals International Inc. buyer in Q3 2018 was Toronto Dominion Bank, an estimated $5.33K added.
- The largest Intellipharmaceuticals International Inc. seller in Q3 2018 was Argent Trust Co, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2018.